Display options
Cite
Jick S, Li L, Gastanaga VM, et al. Prevalence of hypercalcemia of malignancy among pediatric cancer patients in the UK Clinical Practice Research Datalink database. Clin Epidemiol. 2017;9:339-343doi: 10.2147/CLEP.S137616.
Jick, S., Li, L., Gastanaga, V. M., Liede, A., & Hernandez, R. K. (2017). Prevalence of hypercalcemia of malignancy among pediatric cancer patients in the UK Clinical Practice Research Datalink database. Clinical epidemiology, 9339-343. https://doi.org/10.2147/CLEP.S137616
Jick, Susan, et al. "Prevalence of hypercalcemia of malignancy among pediatric cancer patients in the UK Clinical Practice Research Datalink database." Clinical epidemiology vol. 9 (2017): 339-343. doi: https://doi.org/10.2147/CLEP.S137616
Jick S, Li L, Gastanaga VM, Liede A, Hernandez RK. Prevalence of hypercalcemia of malignancy among pediatric cancer patients in the UK Clinical Practice Research Datalink database. Clin Epidemiol. 2017 Jun 15;9:339-343. doi: 10.2147/CLEP.S137616. eCollection 2017. PMID: 28670142; PMCID: PMC5479301.
Copy Download .nbib Format: NLM
Share it on

Clin Epidemiol. 2017 Jun 15;9:339-343. doi: 10.2147/CLEP.S137616. eCollection 2017.

Prevalence of hypercalcemia of malignancy among pediatric cancer patients in the UK Clinical Practice Research Datalink database.

Clinical epidemiology

Susan Jick, Lin Li, Victor M Gastanaga, Alexander Liede, Rohini K Hernandez

Affiliations

  1. Boston Collaborative Drug Surveillance Program, Boston University School of Public Health, Lexington, MA, USA.
  2. Center for Observational Research, Amgen Inc., Thousand Oaks and South San Francisco, CA, USA.

PMID: 28670142 PMCID: PMC5479301 DOI: 10.2147/CLEP.S137616

Abstract

BACKGROUND: The reported proportion of cancer patients who experience hypercalcemia of malignancy (HCM) is low, particularly in the pediatric population, ranging between <1% and 5%. HCM can be observed with any type of tumor in children and occurs most commonly with leukemia. While HCM is a potentially fatal condition, the prevalence of HCM is not well understood in pediatric cancer patients.

METHODS: Using the UK Clinical Practice Research Datalink, we identified pediatric cancer patients with recorded corrected serum calcium (CSC) from 2003 through 2014. Hypercalcemic patients (CSC ≥10.8 mg/dL) were classified into 4 CSC levels. We estimated the annual prevalence of HCM using Byar's method.

RESULTS: Among 517 pediatric cancer patients, leukemia, lymphoma, and brain tumors were the most frequent cancer types. The prevalence of HCM overall (grade 1 or higher) ranged from 0.24% to 0.81% between 2003 and 2014. There were too few cases to compare prevalence by type of cancer.

CONCLUSION: We provide the first systematic analysis using a UK population-based data source to estimate the number of pediatric cancer patients affected with HCM by grade. Our findings showed that the prevalence of pediatric HCM was very low (0.24%-0.81%) over the 12-year study period, which is consistent with previous study of adult cancer patients in the UK (0.20%-0.67%).

Keywords: Clinical Practice Research Datalink; cancer; hypercalcemia; pediatric; prevalence

Conflict of interest statement

Disclosure This study was funded by Amgen Inc. The coauthors VMG, AL, and RKH are employees of Amgen Inc. The authors report no other conflicts of interest in this work.

References

  1. Anticancer Res. 2009 May;29(5):1551-5 - PubMed
  2. Rev Endocr Metab Disord. 2000 Nov;1(4):253-63 - PubMed
  3. J Clin Endocrinol Metab. 2014 Sep;99(9):3144-52 - PubMed
  4. Curr Opin Pediatr. 2010 Aug;22(4):508-15 - PubMed
  5. Cancer Med. 2016 Aug;5(8):2091-100 - PubMed
  6. West J Med. 1990 Dec;153(6):635-40 - PubMed
  7. BMJ. 2015 Jun 02;350:h2723 - PubMed
  8. Acta Med Iran. 2011;49(12):818-23 - PubMed
  9. Cancer Epidemiol. 2015 Dec;39(6):901-7 - PubMed
  10. Curr Med Chem. 2011;18(23):3462-7 - PubMed
  11. Clin J Am Soc Nephrol. 2012 Oct;7(10):1722-9 - PubMed
  12. Semin Nephrol. 2004 Jan;24(1):48-54 - PubMed
  13. Cancer. 1993 Jul 1;72(1):256-60 - PubMed

Publication Types